Usefulness of the CAT, LCOPD, EQ-5D and COPDSS scales in understanding the impact of lung disease in patients with Alpha-1 antitrypsin deficiency

COPD: Journal of Chronic Obstructive Pulmonary Disease

Volumn 11, Issue 5, 2014, Pages 480-488

  Manca, Sandra ^a   Rodriguez, Esther ^b   Huerta, Arturo ^c   Torres, Maria ^d   Lazaro, Lourdes ^e   Curi, Sergio ^f   Pirina, Pietro ^a   Miravitlles, Marc ^b  

^a UNIVERSITY OF SASSARI   (Italy)

^b HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^c INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^d UNIVERSITY HOSPITAL COMPLEX OF VIGO   (Spain)

^e HOSPITAL UNIVERSITARIO DE BURGOS   (Spain)

^f Instituto de Investigación Sanitaria de Navarra   (Spain)

Author keywords

Alpha 1 antitrypsin deficiency; CAT; COPD; COPDSS; EQ 5D; Quality of life

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CORTICOSTEROID; LONG ACTING DRUG; MUCOLYTIC AGENT; MUSCARINIC RECEPTOR BLOCKING AGENT; SHORT ACTING DRUG; THEOPHYLLINE;

ADULT; ALPHA 1 ANTITRYPSIN DEFICIENCY; ARTICLE; CHARLSON COMORBIDITY INDEX; CHRONIC OBSTRUCTIVE LUNG DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE ASSESSMENT TEST; CHRONIC OBSTRUCTIVE LUNG DISEASE SEVERITY SCORE; COMPARATIVE STUDY; CONTROLLED STUDY; CORTICOSTEROID THERAPY; CROSS-SECTIONAL STUDY; EUROQUALITY OF LIFE 5 DIMENSION QUESTIONNAIRE; FEMALE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HUMAN; LIVING WITH CHRONIC OBSTRUCTIVE LUNG DISEASE QUESTIONNAIRE; LUNG EMPHYSEMA; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OBSERVATIONAL STUDY; OXYGEN THERAPY; PRIORITY JOURNAL; QUALITY OF LIFE; QUALITY OF LIFE ASSESSMENT; RESPIRATORY TRACT DISEASE ASSESSMENT; AGED; CASE CONTROL STUDY; HEALTH STATUS; PATHOPHYSIOLOGY; QUESTIONNAIRE; SEVERITY OF ILLNESS INDEX;

AGED; ALPHA 1-ANTITRYPSIN DEFICIENCY; CASE-CONTROL STUDIES; CROSS-SECTIONAL STUDIES; FEMALE; HEALTH STATUS; HUMANS; MALE; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUALITY OF LIFE; QUESTIONNAIRES; SEVERITY OF ILLNESS INDEX;

EID: 84928889630     PISSN: 15412555     EISSN: 15412563     Source Type: Journal    
DOI: 10.3109/15412555.2014.898030     Document Type: Article

References (36)

1. Luisetti M, Seersholm N. α1-Antitrypsin deficiency·1: Epidemiology of α1-antitrypsin deficiency. Thorax 2004; 59:164–169.
2. Miravitlles M. Alpha-1-antitrypsin and other proteinase inhibitors. Curr Opin Pharmacol 2012; 12:309–314.
3. Piitulainen E, Eriksson S. Decline in FEV1 related to smoking status in individuals with severe a1-antitrypsin deficiency (PiZZ) Eur Respir J 1999; 13:247–251.
4. Tirado-Conde G, Lara B, Casas F, Blanco I, Bustamante A, Cadenas S, et al. Factors associated with the evolution of lung function in patients with alpha-1 antitrypsin deficiency in the Spanish Registry. Arch Bronconeumol 2011; 47:495–503.
5. Jones PW, Donohue JF, Nedelman J, Pascoe S, Pinault G, Lassen C. Correlating changes in lung function with patient outcomes in chronic obstructive pulmonary disease: a pooled analysis. Respir Res 2011; 12:161.
6. Renwick DS, Connolly MJ. Impact of obstructive airways disease on quality of life in older adults. Th orax 1996; 51:520–525.
7. Ferrer M, Alonso J, Morera J, Marrades RM, Khalaf A, Aguar C, et al. Chronic obstructive pulmonary disease stage and health-related quality of life. Ann Intern Med 1997; 127:1072–1079.
8. Campos MA, Alazemi S, Zhang G, Salathe M, Wanner A, Sandhaus RA, et al. Clinical characteristics of subjects with symptoms of alpha1-antitrypsin deficiency older than 60 years. Chest. 2009; 135:600–608.
9. Dowson LJ, Guest PJ, Stockley RA. Longitudinal changes in physiological, radiological, and health status measurements in alpha-1 antitrypsin deficiency and factors associated with decline. Am J Respir Crit Care Med 2001; 164:1805–1809.
10. Dowson LJ, Guest PJ, Stockley RA. The relationship of chronic sputum expectoration to physiologic, radiologic, and health status characteristics in alpha-1 antitrypsin deficiency (PiZ). Chest 2002; 122: 1247–1255.
11. Bestall JC, Paul EA, Garrod R, Garnham R, Jones PW, Wedzicha JA. Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease. Thorax 1999; 54:581–586.
12. Eisner MD, Trupin L, Katz PP, Yelin EH, Earnest G, Balmes J, et al. Development and validation of a survey-based COPD Severity Score. Chest 2005; 127: 1890–1897.
13. Miravitlles M, Llor C, de Castellar R, Izquierdo I, Baro E, Donado E. Validation of the COPD severity score for its use in Primary Care. The NEREA study. Eur Respir J 2009; 33: 519–527.
14. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic co-morbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40:373–383.
15. EuroQoL Group. EuroQol: a new facility for the measurement of health-related quality of life. Health Policy 1990; 16:199–208.
16. Badia X, Roset M, Montserrat S, Herdman M, Segura A. The Spanish version of EuroQol: a description and its applications. European quality of life scale. Med Clin (Barc) 1999; 112(Suppl 1):e79–e85.
17. McKenna SP, Meads DM, Doward LC, Twiss J, Pokrzywinski R, Revicki D, Hunter CJ, Glendenning GA. Development and validation of the living with chronic obstructive pulmonary disease questionnaire Qual Life Res 2011; 20:1043–1052.
18. Jones PW, Harding G, Berry P, Wiklund I, Chen WH, Leidy KN. Development and first validation of the COPD Assessment Test. Eur Respir J 2009; 34:648–654.
19. Silverman EK, Pierce JA, Province MA, Rao DC, Campbell EJ. Variability of pulmonary function in alpha-1 antitrypsin deficiency: clinical correlates. Ann Intern Med 1989; 111:982–991.
20. Piras B, Ferrarotti I, Lara B, Martinez MT, Bustamante A, Ottaviani S, et al. Characteristics of Italian and Spanish patients with alpha-1-antitrypsin deficiency: Identifying clinical phenotypes. Eur Respir J 2013; 42:54–64.
21. Jones PW, Quirk FH, Baveystock CM. The St George’s Respiratory Questionnaire. Respir Med 1991; 85(Suppl B):25–31.
22. Ware JE Jr, Sherbourne CD.The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992; 30:473–483.
23. Campos MA, Alazemi S, Zhang G, Wanner A, Salathe M, Baier H, et al. Exacerbations in subjects with alpha-1 antitrypsin deficiency receiving augmentation therapy. Respir Med 2009; 103: 1532–1539.
24. Needham M, Stockley RA. Exacerbations in alpha-1 antitrypsin deficiency. Eur Respir J 2005; 25: 992–1000.
25. Stolk J, Ng WH, Bakker ME, Reiber JHC, Rabe KF, Putter H, Stoel BC. Correlation between anual change in health status and computer tomography derived lung density in subjects with alpha-1 antitrypsin deficiency. Thorax 2003; 58:1027–1030.
26. Dowson LJ, Newall C, Guest PJ, Hill SL, Stockley RA. Exercise capacity predicts health status in alpha-1 antitrypsin deficiency. Am J Respir Crit Care Med 2001; 163:936–941.
27. Holm KE, Borson S, Sandhaus RA, Ford DW, Strange C, Bowler RP, et al. Diff erences in adjustement between individuals with alpha-1 antitrypsin deficiency (AATD)-associated COPD and non-AATD COPD. COPD 2013; 10: 226–234.
28. Jones P, Miravitlles M, van der Molen T, Kulich K. Beyond FEV1 in COPD—A review of patient-reported outcomes and their measurement using a new generation of instruments. Int J Chron Obst Pulm Dis 2012; 7: 697–709.
29. Edgar RG, Griffiths D, Stockley RA. Validations of the COPD Assessment Test (CAT) whithin alpha-1 antitrypsin deficiency (AATD). Thorax 2010; 65: A141.
30. Jones PW, Brusselle G, Dal Negro RW, Ferrer M, Kardos P, Levy ML, et al. Properties of the COPD assessment test in a cross-sectional European study Eur Respir J 2011; 38:29–35.
31. Pillai AP, Turner AM, Stockley RA. Global initiative for chronic obstructive lung disease 2011 symptom/risk assessment in α1-antitrypsin deficiency. Chest 2013; 144:1152–1162.
32. Miravitlles M, Soler-Cataluna JJ, Calle M, Molina J, Almagro P, Quintano JA et al. Spanish COPD guidelines (GesEPOC). Pharmacological treatment of stable COPD. Arch Bronconeumol 2012; 48: 247–257.
33. Miravitlles M, Iriberri M, Barrueco M, Lleonart M, Villarrubia E, Galera J. Usefulness of the LCOPD, CAFS, and CASIS scales in understanding the impact of COPD on patients. Respiration 2013; 86:190–200.
34. McKenna SP, Twiss J, Crawford SR, Oprandi NC, Tammaru M, Miravitlles M. Adapting the Living with Chronic Obstructive Pulmonary Disease (LCOPD) for use in Southern European (Italian and Spanish) and Eastern European (Russian) cultures. J Clin Epidemiol 2012; 65: 906–914.
35. Eisner MD, Omachi TA, Katz PP, Yelin EH, Iribarren C, Blanc PD. Measurement of COPD severity using a surveybased score: validation in a clinically and physiologically characterized cohort. Chest 2010; 137:846–851.
36. Miravitlles M, Izquierdo I, Herrejon A, Torres VJ, Baro E, Borja J. On behalf of the ESFERA investigators COPD severity score as a predictor of failure in exacerbations of COPD. The ESFERA study. Respir Med 2011; 105:740–747.